Last reviewed · How we verify
Cell-culture
At a glance
| Generic name | Cell-culture |
|---|---|
| Also known as | Flucelvax Quadrivalent |
| Sponsor | Marshfield Clinic Research Foundation |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group (PHASE3)
- In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs
- T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation (PHASE1)
- ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (PHASE1, PHASE2)
- A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |